Search results
24 paź 2023 · The pulmonary function test (PFT) has been widely used in sarcoidosis. It may vary due to the severity, extent, and the presence of complications of the disease. Although the PFT of most sarcoidosis patients is normal, there are still 10–30% of cases who may experience a decrease in the PFT, with a progressive involvement of lungs.
For patients with sarcoidosis in whom pulmonary hypertension (PH) is suspected, we suggest initial testing with TTE (conditional recommendation, very low-quality evidence).
24 paź 2023 · The pulmonary function test (PFT) has been widely used in sarcoidosis. It may vary due to the severity, extent, and the presence of complications of the disease. Although the PFT of most sarcoidosis patients is normal, there are still 10–30% of cases who may experience a decrease in the PFT, with a progressive involvement of lungs.
29 kwi 2024 · Pulmonary function testing — Pulmonary function tests (PFTs), including spirometry and diffusing capacity for carbon monoxide (DLCO) are obtained in patients with pulmonary sarcoidosis to assess the severity of respiratory impairment and to monitor the course of disease. PFTs are not a reliable means for detecting the presence or extent of ...
The literature on pulmonary function testing in sarcoidosis is critically reviewed. The results indicate that pulmonary function tests are not a reliable means for detecting the presence of parenchymal sarcoidosis, nor do they provide an accurate estimate of the extent of parenchymal disease.
Oral glucocorticoids with or without another immunosuppressive agent are the first-line therapy for symptomatic patients with abnormal pulmonary function test results and lung infiltrates. Patients with sarcoidosis and precapillary pulmonary hypertension should be treated with therapies such as phosphodiesterase inhibitors and prostacyclin ...
6 cze 2021 · Among the results of lung function tests, forced vital capacity (FVC) is an important parameter for monitoring disease (and response to treatment) in pulmonary sarcoidosis; the diffusing capacity of the lung for carbon monoxide (DLco) and forced expiratory volume in the first second (FEV1) are also important . A Delphi panel agreed that changes ...
